|Bid||142.56 x 200|
|Ask||142.58 x 400|
|Day's Range||141.83 - 143.60|
|52 Week Range||109.32 - 143.60|
|PE Ratio (TTM)||24.08|
|Forward Dividend & Yield||3.36 (2.39%)|
|1y Target Est||N/A|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.
Stocks hit record highs on IBM, J&J, Adobe and the Senate's step toward tax cuts. Netflix wowed analysts, but investors gave mixed reviews. United Airlines and General Electric plunged.
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
Alcobra Ltd (NASDAQ:ADHD) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 40% upturn. Alcobra's wholly-owned subsidiary, Arcturus, announced that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals - a subsidiary of Johnson & Johnson. According to the agreement, the two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform.
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
NYSE floor trader Kenny Polcari recalls the 1987 market crash in detail and says it could happen again ... only it would be a lot faster this time.
Jim Cramer pinpoints the windows of opportunity in the market-wide sell-off and helps investors strategize how to play the decline.
The "Squawk on the Street" news crew share their thoughts on the 1987 crash of the markets where the Dow shed almost 23 percent and lost half a trillion dollars in market value.